BlueCrest Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

BlueCrest Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-26,750	Closed	-$58K	–	710
2019 Q3	$58K	Buy	+26,750	New	+$71.5K	﹤0.01%	550
2018 Q4	–	Sell	-191,241	Closed	-$503K	–	1743
2018 Q3	$503K	Buy	+191,241	New	+$469K	0.01%	749
2018 Q2	–	Sell	-30,277	Closed	-$89K	–	2091
2018 Q1	$89K	Buy	+30,277	New	+$82.6K	﹤0.01%	1382
2017 Q4	–	Sell	-25,453	Closed	-$86K	–	1244
2017 Q3	$86K	Buy	25,453 +14,391	+130%	+$40K	﹤0.01%	798
2017 Q2	$27K	Buy	+11,062	New	+$25.4K	﹤0.01%	879

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlueCrest Capital Management's PDLI Position: Q4 2019 in Review

BlueCrest Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 26,750 shares — an estimated $58K sold.

BlueCrest Capital Management first reported a position in PDLI in Q2 2017 and held it in 5 quarters. The position peaked at $503K in Q3 2018. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

BlueCrest Capital Management reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 26,750 PDL BioPharma, Inc. shares in Q4 2019, an estimated $58K.
BlueCrest Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2017 and held it in 5 quarters.
BlueCrest Capital Management's PDL BioPharma, Inc. position peaked at $503K in Q3 2018.
150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.